Completed PHASE4 INTERVENTIONAL 2-arm NCT00520260

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients

Sponsor: Bausch & Lomb Incorporated

Conditions Dry Eye Disease Ocular Comfort

Interventions bromfenac ketorolac

Updated 5 times since 2017 Last updated: Feb 17, 2009 Started: Aug 31, 2007 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Dry Eye Disease and Ocular Comfort and is currently completed. Bausch & Lomb Incorporated leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated
Florida Eye Microsurgical Institute

Data source: Florida Eye Microsurgical Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boynton Beach, United States